New Director joins Board of Directors
Sydney, Feb 25, 2015 AEST (ABN Newswire) - Regenerative medicine company, Regeneus Ltd (
ASX:RGS) is pleased to announce the appointment of Dr Glen Richards as an independent non-executive director of Regeneus with effect from April.
Dr Richards was the founding Managing Director of Greencross (ASX:GXL)and over 20 years built it into Australia's largest veterinary healthcare group with over 115 veterinary practices and 195 vet specialty stores and led its merger with Petbarn. Dr Richards continues as a non-executive director of Greencross.
Dr Richards said: " I'm pleased to join the Board of Regeneus and look forward to making a contribution to the growth and success of the company. I believe that cell based regenerative medicine will play an important role in the future of veterinary and human healthcare and I look forward to Regeneus playing a leading role in bringing new and useful cell therapies to market".
Regeneus Chairman, Dr Roger Aston said: "On behalf of the Directors, I welcome Glen to the Regeneus Board. Dr Richards has a rare combination of clinical and business experience gained from his leadership role in building Greencross into Australia's leading veterinary healthcare group. His skills, experience and network make him a valuable and strategic addition to the Board particularly as we develop and commercialise our veterinary products for musculoskeletal disease and oncology conditions".
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.
| ||
|
